Literature DB >> 15306751

Long term use of oral contraceptives without thrombosis in patients with FV Leiden polymorphism: a study of 37 patients (2 homozygous and 35 heterozygous).

A Girolami1, D Tormene, S Gavasso, C Bertolo, B Girolami.   

Abstract

It is commonly accepted that women on oral contraceptive therapy have about a four fold increased incidence of venous thrombosis in comparison to non users. Women with FV Leiden polymorphism have an even higher incidence. The purpose of the paper is to show that women with FV Leiden polymorphism may sometimes remain asymptomatic in spite of long-term use of oral contraceptives. We have studied and followed 37 women with this polymorphism (35 heterozygotes and 2 homozygotes) who remained asymptomatic even after a long use, occasionally up to 10-12 years of oral contraception. Furthermore, these women remained asymptomatic in spite of the fact that the majority of them took preparations containing third generation progestins (gestodene or desogestrel). These progestins are considered to be more thrombogenic as compared to older ones. Finally, several of these women became pregnant before, during interruptions or after the contraceptive therapy and remained also asymptomatic but for one patient with varicose veins who developed superficial phlebitis during one pregnancy. These data indicate that FV Leiden polymorphism, as far as oral contraceptive therapy is concerned, is not a very strong prothrombotic condition and probably does not represent an absolute contraindication to its use. Unfortunately so far there is no sure way to distinguish the women with this polymorphism who will develop venous thrombosis from those who will remain asymptomatic during oral contraceptive therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15306751     DOI: 10.1023/B:THRO.0000037671.98201.15

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  25 in total

1.  Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism.

Authors:  P de Moerloose; G Reber; A Perrier; T Perneger; H Bounameaux
Journal:  Br J Haematol       Date:  2000-07       Impact factor: 6.998

Review 2.  Blood coagulation and oral contraceptives. A critical review.

Authors:  U H Winkler
Journal:  Contraception       Date:  1998-03       Impact factor: 3.375

3.  Emphasis on congenital conditions predisposing to thrombosis should not make us disregard the importance of acquired factors.

Authors:  A Girolami; L Scarano; B Girolami; A Marchiori
Journal:  Blood Coagul Fibrinolysis       Date:  1998-10       Impact factor: 1.276

4.  Oral contraceptives and venous thromboembolism: findings in a large prospective study.

Authors:  M Vessey; D Mant; A Smith; D Yeates
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-22

5.  Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis.

Authors:  P Simioni; P Prandoni; A W Lensing; D Manfrin; D Tormene; S Gavasso; B Girolami; C Sardella; M Prins; A Girolami
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

6.  Venous thromboembolism in relation to oral contraceptive use.

Authors:  S P Helmrich; L Rosenberg; D W Kaufman; B Strom; S Shapiro
Journal:  Obstet Gynecol       Date:  1987-01       Impact factor: 7.661

7.  Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

Authors: 
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

8.  Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

Authors: 
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

9.  Changes in prescription patterns of oral contraceptives in a northern Italian province: relation with venous thromboembolism.

Authors:  Antonio Girolami; Luca Spiezia; Fabrizio Vianello; Bruno Girolami; Fabrizio Fabris
Journal:  Clin Appl Thromb Hemost       Date:  2003-04       Impact factor: 2.389

10.  Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden.

Authors:  C Rintelen; C Mannhalter; H Ireland; D A Lane; P Knöbl; K Lechner; I Pabinger
Journal:  Br J Haematol       Date:  1996-05       Impact factor: 6.998

View more
  1 in total

1.  Arterial thrombosis and drospirenone-containing pill (Yasmin). Is the pill to be absolutely avoided by women who smoke?

Authors:  Antonio Girolami; Fabiana Tezza; Emanuele Allemand; Bruno Girolami
Journal:  J Thromb Thrombolysis       Date:  2007-12-23       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.